WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, will sponsor a breakfast symposium entitled "Robotic Therapy – Current Applications & Future Vision" on Monday, October 31 at 7:00 a.m. at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2016 conference. TCT, the largest educational meeting in the world specializing in interventional cardiovascular medicine, will take place from Saturday, October 29 through Wednesday, November 2 at the Walter E. Washington Convention Center in Washington, D.C.
The breakfast symposium will be chaired by Martin B. Leon, M.D., Director, Center for Interventional Vascular Therapy NewYork-Presbyterian Hospital/Columbia University Medical Center and Chairman Emeritus of the Cardiovascular Research Foundation (CRF), and will also feature a faculty of leading interventional cardiologists. An audience discussion and Q&A session will follow the presentations.
"I'm excited to present the vision of where robotic therapy fits in the future of the cath lab. Robotics may become very important to protect practitioners and to reduce variability and improve clinical outcomes," said Dr. Leon.
Mark Toland, Corindus President and CEO, stated, "As adoption of robotic therapy in PCI continues to grow, we see that success comes when facilities build comprehensive robotic programs to maximize the benefit of cardiovascular robotics. This symposium will educate attendees on how current users have successfully developed programs and outline the future that we see for robotics in the cath lab."
"Robotic Therapy – Current Applications & Future Vision" will feature the following speakers and topics:
- "Robotic Therapy: Past, Present & Future" with Martin B. Leon, M.D.
- "Building a Successful Vascular Robotic Program" with Gregory A. Helmer, M.D., University of Minnesota & Fairview Hospitals; Edina, MN
- "Evidence for Robotic Therapy: From Cath Lab Wellness to Patient Benefits" with Ryan D. Madder, M.D., Frederik Meijer Heart & Vascular Institute, Spectrum Health; Grand Rapids, MI
- "Complex Robotic Intervention" with Ehtisham Mahmud, M.D., UC San Diego School of Medicine; La Jolla, CA
Corindus' CorPath System is the first and only FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention procedures while protecting medical professionals from radiation exposure occurring in hospital cath labs. By bringing robotic precision to complex, radial, coronary and peripheral procedures, the CorPath System helps optimize clinical outcomes and minimize costs associated with manual procedures.
Space for the symposium is limited. For more information and to register for the symposium, visit www.tctconference.com/satelliteprograms.
To take advantage of an exclusive opportunity to use the CorPath System with an advanced simulator, register here and visit Corindus at booth #1322 at TCT 2016.
About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to complex, radial, coronary and peripheral procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.